CommercialPrior AuthMedium impact
08.01.57a, Lutathera® (Lutetium Lu 177 Dotatate) (Independence Administrators)
Independence Blue Cross·Oncology, Nuclear Medicine, Radiation Oncology·Pharmacy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators has updated medical necessity criteria for Lutathera® (Lutetium Lu 177 Dotatate), a radiopharmaceutical therapy for neuroendocrine tumors. This recent policy change (effective 01/27/2025) modifies prior authorization and coverage requirements. The billing team must review updated clinical criteria to ensure claims meet new medical necessity standards.
Action Required
By February 15, 2025: Billing team and providers must obtain and review the full Lutathera policy text (08.01.57a) from Independence Administrators at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx. Identify specific medical necessity criteria changes and update: (1) Prior authorization templates to reflect new criteria, (2) Billing software to enforce updated requirements before claim submission, (3) Provider documentation checklists in EHR to capture required clinical information (diagnosis, staging, performance status, prior treatments, etc.). Before submitting any Lutathera claims after 01/27/2025, verify patient documentation meets new medical necessity standards. Claims submitted without updated medical necessity documentation will likely be denied by Independence Administrators.